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Intravenous Magnesium Sulfate Use in Hip Arthroscopy Patients and Anesthesia
Provider Satisfaction with Patient Care at an Ambulatory Surgery Center
Abstract
Hip arthroscopy patients experience high levels of postoperative pain. Intravenous (IV) magnesium
sulfate is widely used in anesthesia practice as a multimodal analgesic but is infrequently utilized at Penn
Presbyterian Medical Center (PPMC). Does the option of adding intravenous magnesium sulfate to the
current pain pathway increase provider satisfaction with patient care and magnesium use? The purpose
was to add IV magnesium sulfate to the multimodal analgesic pathway for hip arthroscopy patients to
evaluate anesthesia provider satisfaction and use of IV magnesium sulfate. The Middle Range Theory of
Acute Pain was used to provide a theoretical framework. The conceptual framework utilized was the PlanDo-Study-Act cycle. Anesthesia providers were refamiliarized with IV magnesium sulfate's analgesic
properties to encourage its administration in hip arthroscopy procedures yielding high levels of
postoperative pain. A survey was distributed to assess provider satisfaction using the Accessibility of
Intervention Measure (AIM) and magnesium use. Frequency counts were used to determine provider
satisfaction with patient care and a run-chart was created to analyze changes in IV magnesium sulfate
usage before and after implementation. Compared to the pre-implementation phase, there was an 85.7%
increase in IV magnesium use among anesthesia providers. Over 12 weeks, ten CRNAs participated in a
total of fourteen hip arthroscopy cases. Nine out of ten providers would consider using magnesium in
future practice. The project served to re-introduce IV magnesium sulfate as an analgesic adjunct for many
surgical procedures and hoped to promote a culture that utilizes IV magnesium sulfate readily.
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Abstract
Hip arthroscopy patients experience high levels of postoperative pain. Intravenous (IV)
magnesium sulfate is widely used in anesthesia practice as a multimodal analgesic but is
infrequently utilized at Penn Presbyterian Medical Center (PPMC). Does the option of adding
intravenous magnesium sulfate to the current pain pathway increase provider satisfaction with
patient care and magnesium use?
The purpose was to add IV magnesium sulfate to the multimodal analgesic pathway for hip
arthroscopy patients to evaluate anesthesia provider satisfaction and use of IV magnesium
sulfate. The Middle Range Theory of Acute Pain was used to provide a theoretical framework.
The conceptual framework utilized was the Plan-Do-Study-Act cycle. Anesthesia providers were
refamiliarized with IV magnesium sulfate's analgesic properties to encourage its administration
in hip arthroscopy procedures yielding high levels of postoperative pain. A survey was
distributed to assess provider satisfaction using the Accessibility of Intervention Measure (AIM)
and magnesium use. Frequency counts were used to determine provider satisfaction with patient
care and a run-chart was created to analyze changes in IV magnesium sulfate usage before and
after implementation. Compared to the pre-implementation phase, there was an 85.7% increase
in IV magnesium use among anesthesia providers. Over 12 weeks, ten CRNAs participated in a
total of fourteen hip arthroscopy cases. Nine out of ten providers would consider using
magnesium in future practice. The project served to re-introduce IV magnesium sulfate as an
analgesic adjunct for many surgical procedures and hoped to promote a culture that utilizes IV
magnesium sulfate readily.
Keywords: magnesium, anesthesia, perioperative, multimodal analgesia, provider
satisfaction
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Intravenous Magnesium Sulfate Use in Hip Arthroscopy Patients and Anesthesia Provider
Satisfaction with Patient Care at an Ambulatory Surgery Center
Multimodal analgesia is now the desired approach for managing perioperative pain, as
heavy opioid administration is discouraged for its addictive nature and undesirable adverse
effects. Numerous studies have shown that magnesium sulfate, among other agents, is a powerful
analgesic adjunct. When used intraoperatively, magnesium sulfate can help reduce postoperative
pain and opioid consumption. This will decrease recovery times, improve patient satisfaction,
decrease healthcare costs, and lighten the burden of the opioid crisis.
Background and Significance
Postoperative pain is associated with delayed recovery, decreased patient satisfaction,
prolonged hospitalizations, and increased healthcare costs (Mitra et al., 2018) when managed
poorly. Undertreated pain at the time of surgery predisposes patients to post-surgical pain and
long-term neuropathic pain (Mitra et al., 2018; Ramaswamy & Colvin, 2013). Historically,
opioids have been the primary analgesic agent used in the perioperative period, but its use is
limited by their adverse effects especially when used as the sole analgesic agent. Perioperative
use of opioids increases the incidence of postoperative nausea and vomiting (PONV), dosedependent respiratory depression, delayed emergence from anesthesia, and physical dependence
(Mitra et al., 2018). Opioid use is also associated with adverse side effects such as pruritus,
urinary retention, ileus, constipation, dysphoria, and muscle rigidity (Yaster et al., 2017). More
recently, there have been reports of dose-dependent hyperalgesia, paradoxical acute and chronic
pain, and immunomodulation effects (Mitra et al., 2018; Ramaswamy & Colvin, 2013; Beloeil,
2019) with opioid use. Older adults, chronically ill patients, and pregnant women are especially
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vulnerable to developing such side effects. Furthermore, the persistent concerns regarding the
opioid crisis in North America have increased the interest in developing techniques to replace or
reduce opioid use perioperatively.
Multiple variables contribute to postoperative pain. To date, no single pharmacological
agent has proven to be effective in decreasing postoperative pain scores without significant side
effects (Ziemann-Gimmel et al., 2014). Over the last decade, multimodal analgesia (MMA) has
emerged as the gold standard of perioperative analgesia. It is associated with reduced
perioperative opioid use, decreased rates of adverse effects, stable intraoperative hemodynamic
reactions, early mobilization, and reduced risks of chronic opioid use (Mitra et al., 2018; Yaster
et al., 2017). MMA promotes the use of various agents targeting different pain receptors and
pathways to achieve a synergistic analgesic effect. It has become an essential component in the
Enhanced Recovery after Surgery (ERAS) or Opioid-Free Anesthesia (OFA) protocols (Shipton
et al., 2018; Beloeil, 2019; Yaster et al., 2017). Several non-opioid based adjuncts have been
frequently used, including ketamine, lidocaine, nonsteroidal anti-inflammatory drugs (NSAIDs),
dexmedetomidine, gabapentinoids, neuraxial anesthesia, and peripheral nerve blocks (Mitra et
al., 2018; Ramaswamy & Colvin, 2013; Beloeil, 2019).
Magnesium sulfate is an agent that has been widely used as a powerful analgesic adjunct
due to its ability to antagonize N-methyl-D-aspartate (NMDA) receptors. Studies have
demonstrated its effectiveness in stabilizing perioperative hemodynamics (Herroeder et al.,
2011). A large number of clinical studies have shown the effectiveness of intraoperative
administration of magnesium in decreasing opioid consumption and improving postoperative
pain outcomes in a variety of procedures (Herroeder et al., 2011; Na et al., 2011). The American
Society of Regional Anesthesia and Pain Medicine recommends incorporating the intraoperative

MAGNESIUM UTILIZATION IN HIP ARTHROSCOPY

5

administration of intravenous (IV) magnesium sulfate as an analgesic adjunct in perioperative
care (George et al., 2018). Magnesium is effective in blunting somatic and autonomic reflexes by
inhibiting catecholamine release associated with surgery. In addition, it reduces intraoperative
anesthetic consumption and decreases muscle relaxant requirements (Herroeder et al., 2011; Na
et al., 2011; Do, 2013; Rodríguez-Rubio et al., 2017). All of the benefits of magnesium sulfate
make it a favorable option for intraoperative use.
The number of hip arthroscopy cases has increased in the recent decade, attributed to its
wide variety of indications to see a magnified view of the joint in a minimally invasive way.
Patients are typically discharged from the Post Anesthesia Care Unit (PACU) the same day if no
complications arise. However, despite being minimally invasive, there is a wide range of
reported postoperative pain scores after hip arthroscopy. Ward et al. (2012) reported 90% of
patients who experience moderate to severe pain after hip arthroscopy was due to manipulation
of the intra-articulated compartment with different sensory nerves that innervate the hip joint
such as the femoral, obturator, and sciatic nerves. Pain could also be due to the traction pressure
caused by irrigation fluids. The swelling after surgery can further increase pain and delay healing
(Bech et al., 2016). Undertreated pain delays PACU discharge, decreases patient satisfaction, as
well as provider satisfaction in patient care. Therefore, with supporting evidence, this quality
improvement proposal calls for the inclusion of magnesium sulfate in a multimodal analgesic
pathway for patients undergoing hip arthroscopy.
Problem Statement and Clinical Question
Hip arthroscopy patients experience high levels of postoperative pain, leading to
increased rescue analgesic consumption and decreased patient satisfaction. Magnesium sulfate is
widely used in anesthesia practice as a multimodal analgesic but is infrequently utilized at Penn
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Presbyterian Medical Center. Does adding IV magnesium sulfate to the current multimodal
analgesic pathway increase magnesium use and provider satisfaction with patient care?
Literature Review
Methods
This review was guided by the integrative review methodology outlined by Whittemore
and Knafl (2005), which provided a research framework to combine and analyze diverse data
utilizing evidence such as integrative reviews, systematic reviews, and meta-analysis. This multistep research strategy allowed for complex perspectives and clinical findings to be synthesized
into one comprehensive review for the topic of interest, which can then be used as the basis for
clinical practices.
Our literature search, article selection, and evaluation were guided by PRISMA
(Preferred Reporting Items for Systematic Reviews and Meta-Analyses) (Appendix D). A
literature search was conducted using two electronic databases: PubMed and Embase. The
following National Library of Medicine Medical Subject Heading (MeSH) terms and keywords
were used in PubMed, ("Surgical Procedures, Operative"[Mesh]) OR "Surgery Department,
Hospital"[Mesh]) OR "Intraoperative Period"[Mesh] OR perioperative* OR operative OR
intraoperative* OR postoperative OR postop*) AND ("Magnesium Sulfate") AND (Iv OR
intravenous OR infusion) AND (anesthesia OR anaesthesia OR "Anesthesia, General"[Mesh]
OR "Anesthesia"[Mesh] OR "Anesthesia and Analgesia"[Mesh]) AND (pain OR pain*). After
limiting the search to articles that studied the adult population and were written in the English
language, PubMed yielded 42 articles. The following search strategy was used in Embase:
(surgery OR surgical OR intraoperative OR perioperative OR 'general anesthesia'/exp OR
'procedures'/exp) NOT 'obstetric procedure'/exp NOT 'pregnancy'/exp AND 'magnesium
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sulfate'/exp AND infusion AND ('analgesia'/exp OR pain). After the results were filtered by the
adult population, Embase yielded 159 articles. Articles from PubMed and Embase were exported
to RefWorks and 15 duplicates were removed. The titles and abstracts of the 186 articles were
screened independently by the project leaders of this review based on the inclusion and exclusion
criteria.
Inclusion criteria included 1) articles written in English; 2) studies sample defined as
adult population; 3) search terms found in the title or within keywords; 4) studies of IV
magnesium sulfate administration compared to placebo or another analgesic agent; 5) studies of
intraoperative magnesium administration. Exclusion criteria included 1) articles related to nonadult populations; 2) case studies, commentaries, clinical review articles, editorials; 3) studies of
magnesium administration outside of the intraoperative period; 4) studies with the experimental
group being non-IV magnesium as a route of administration. This search strategy yielded 82
articles and excluded 104 articles. After reading full-text articles and excluding studies published
before 2015, a total of 38 articles were chosen. A total of ten articles were included in the Table
of Evidence and were graded using the Johns Hopkins Nursing Evidence-Based Practice
Research Appraisal Guidelines (Philbrick, 2013). The design and quality of evidence of the
articles were assigned an evidence level of I, II, III, IV, or V and graded A (high quality) B
(good quality), or C (low quality or major flows) (Table 2).
All 38 articles selected were quantitative studies and were published between 2015 to
2020. Thirty-six articles were double-blind randomized control trials (RCT), one was an
observational study, and one was a prospective cross-sectional study. For the ten studies included
in the Table of Evidence, the effect of IV magnesium sulfate administration on postoperative
pain was compared to either placebo (normal saline) or other analgesic adjunct(s). Of the ten

MAGNESIUM UTILIZATION IN HIP ARTHROSCOPY

8

studies, seven measured postoperative pain scores using the Visual Analogue Scale (VAS), and
one used the Numeric Rating Scale (NRS). These seven studies also measured secondary
outcomes such as magnesium's effect on tourniquet-induced pain, sensory and motor blockade of
neuraxial anesthesia, and postoperative analgesia consumptions. The two studies that did not
measure postoperative pain using VAS or NRS measured the consumption of PCA and rescue
analgesia, pulmonary function test results, and length of mechanical ventilation. The Synthesized
Table of Evidence (Table 1) compares various populations, anesthetic type, magnesium
treatment, evaluation time, and measurement.
Of the studies reported, three themes were identified and analyzed: 1) the effect of IV
magnesium sulfate administration on postoperative pain scores and analgesic requirements; 2)
onset and duration of perioperative analgesia from magnesium and 3) the long-term benefits of
pain control to overall health. IV magnesium sulfate was selected as the choice of analgesic
adjunct to add to the current analgesic pathway due to these various benefits.
Findings
Literature suggests IV magnesium sulfate to be an effective analgesic adjunct for various
surgical procedures. A bolus and/or infusion of magnesium decreases pain scores, PCA
consumption, and rescue analgesic consumption in adult surgical patients undergoing either
general or neuraxial anesthesia.
Dehkordy et al. (2020) conducted a double-blind RCT in adult patients who underwent
posterior lumbar surgery. In the RCT, patients were randomly assigned to receive a magnesium
bolus of 50mg/kg and a continuous infusion of 15mg/kg/h throughout the operation; or the
control group, to receive the same volume in isotonic saline. Dehkordy et al. (2020) found that in
adult surgical patients undergoing posterior lumbar surgery, the PCA morphine consumption was
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significantly lower in patients who received the IV bolus and infusion of magnesium sulfate
compared to the control group, who received only isotonic saline. A similarly structured RCT
was conducted by Jarahzadeh et al. (2016) and studied IV magnesium sulfate's analgesic effects
on patients undergoing a total abdominal hysterectomy (TAH). Pain scores measured with VAS
were significantly lower up to six hours after TAH and opioid requirements decreased within the
group that received a magnesium sulfate bolus and infusion intraoperatively (Jarahzadeh et al.,
2016). Pain scores measured with VAS and postoperative PCA morphine requirements also
decreased after a bolus and infusion of magnesium in women having a cesarean section under
general anesthesia (Mireskandari et al., 2015).
An IV magnesium sulfate infusion not only effectively decreased pain scores in patients
undergoing general anesthesia, but also in those receiving regional anesthesia. Shah et al. (2016)
conducted an RCT to determine the analgesic effects of magnesium sulfate on adult patients
undergoing lower abdominal or lower limb surgery with spinal anesthesia. Postoperative pain
scores assessed with VAS and rescue analgesic requirements were significantly lower in patients
who had received a magnesium sulfate bolus and infusion, compared to patients who only
received normal saline with their spinal anesthetic (Shah et al., 2016). Sahar et al. (2017)
performed a similar RCT to assess whether IV magnesium sulfate attenuates tourniquet pain and
reduces postoperative analgesic requirements in patients undergoing arthroscopic knee surgery
with epidural anesthesia. The study found that in the patients who received a bolus and infusion
of magnesium sulfate, tourniquet pain and intraoperative fentanyl requirements were decreased,
as well as postoperative analgesic requirements (Sahar et al., 2017).
After an in-depth review of the literature, research suggests that intraoperative IV
magnesium sulfate attenuates pain. Research studies were conducted on a variety of surgical
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procedures, including orthopedics, bariatric, thoracic, and transplant surgery. Research studies
mostly included the American Society of Anesthesiologist (ASA) class I-II of adult ranges.
Exclusion criteria included hepatic, cardiovascular, renal dysfunction, neuromuscular diseases,
coagulopathy, pre-existing pain syndromes, opioid abuse, prior treatment with calcium channel
blockers or beta-blockers, heart blocks, hypermagnesemia, or an allergy to the treatment drug.
Across research studies, intraoperative IV magnesium sulfate treatment included either a bolus
dose of 30-50 mg/kg, an infusion of 10-15 mg/kg/h, or both. Postoperatively, pain scores and
analgesic requirements were monitored for four to forty-eight hours.
All research studies within the literature review displayed decreases in pain scores and
analgesic requirements postoperatively. Many studies displayed significant decreases in pain
scores and analgesic requirements throughout the postoperative evaluation period for groups that
received IV magnesium. One exception to this was found within the Taheri et al. (2015) study
involving women undergoing a TAH with general anesthesia. The study group received a single
magnesium bolus of 50mg/kg within 15 minutes of induction while the control group received a
normal saline bolus. The study found that postoperative pain scores were significantly lower in
the study group at 6, 12, and 24-hour time intervals, but there were no significant differences at
the time of emergence. Despite these findings, analgesic requirements were significantly lower in
the study group throughout the entire 24-hour postoperative period.
The current multimodal analgesic pathway for patients undergoing hip arthroscopy
procedures includes a fascia iliaca nerve block. The use of peripheral nerve blockade for hip
arthroscopy provides early postoperative pain control, minimizes opioid consumption, and
facilitates discharge from the ambulatory surgical center with high-quality pain relief and overall
patient satisfaction (Krych et al., 2014). Fascia iliaca blocks involve injecting a local anesthetic
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into the fascia iliaca compartment, anesthetizing the articular branches of the femoral, lateral
femoral cutaneous, and obturator nerves that innervate the hip capsule and related structures that
are traumatized during hip arthroscopy (Kunze et al., 2020). Studies of hip arthroscopies utilizing
fascia iliaca blocks have shown to provide adequate pain control and decreased opioid use after
hip arthroscopy, with minimal complications (Kay et al., 2016). However, despite utilization of
the fascia iliaca block, patients still report significant levels of pain and often require additional
opioid consumption in the immediate postoperative period. Including IV magnesium sulfate as
an additional adjunct addresses the issue of significant postoperative pain encountered with the
fascia iliaca block, improving the current multimodal pathway.
Limitations
Limitations found in the literature review include small sample sizes and varying
methods of magnesium administration. Determining the optimal method of administration (bolus
dose vs. continuous infusion, weight-based dosing vs. set dose) was inconclusive. It was also
unknown as to whether patients were naïve or opioid-tolerant based on the studies. Despite these
factors, the collective research on intraoperative magnesium sulfate administration suggests
analgesic effects potent enough to decrease pain scores and reduce opioid requirements, in
addition to many other potential benefits. Regardless of surgery type and the various routes of
magnesium administration used among 38 studies, the profound effect on analgesia up to 48
hours into the postoperative period remained consistent throughout the literature.
Organizational Assessment
Penn Presbyterian Medical Center (PPMC) is a level I trauma center nestled in the heart
of University City. It is a hospital owned by Penn Medicine that largely serves the West
Philadelphia community. PPMC strives to improve the health and well-being of people through
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research, education, clinical care, and community service. The institution seeks to embrace the
opportunity to teach others, learn from their partners, and provide care with dignity and skill.
Within the Penn Medicine University City building is an Ambulatory Surgery Center (ASC),
which holds the same values as its parent hospital, PPMC. Anesthesia providers at PPMC also
provide anesthesia care at ASC. Due to the ambulatory nature and necessity of same-day
discharge at this site, pain management is narcotic-limited and NSAID-heavy. Anesthesia
providers err on the side of caution with opioid administration to prevent postoperative
respiratory depression, a major factor contributing to delays in discharge. The current
multimodal analgesic pathway for hip arthroscopy patients at this ambulatory surgery center
includes general anesthesia with a fascia iliac block. The dosage and choice of intravenous
analgesic administration varies among anesthesia providers. In general, IV magnesium sulfate is
inconsistently used by anesthesia providers.
A needs assessment of the organization and problem severity were analyzed. Upon
discussion with a staff member at the surgical center, it was discovered that hip arthroscopy
procedures were known to cause much pain and discomfort for these surgical patients. Our needs
assessment revealed that hip arthroscopy patients had high rates of postoperative pain, which
decreased provider satisfaction with their anesthetic care and had implications on discharge time
and postoperative pain scores. Magnesium sulfate had been inconsistently used at PPMC,
although some providers did use it in various surgical procedures. Adding the option of IV
magnesium sulfate to the current multimodal analgesic pathway served as a reminder to
providers of this analgesic adjunct that had already been proven to efficaciously promote
multimodal analgesia and had been widely utilized in other departments and healthcare facilities.

MAGNESIUM UTILIZATION IN HIP ARTHROSCOPY

13

Some internal factors that impacted the project included finding a surgeon whose goals
aligned with this project, was willing to accept this project for their cases, and the availability of
IV magnesium sulfate at the ambulatory surgery center.
Key stakeholders of this quality improvement project included: the PPMC Director of
Anesthesia (Dr. Mark Pizzini), the chief CRNA (Ed Czerpak MSN), PPMC site lead (Dr.
Badiola), University of Pennsylvania faculty lead (Dr. Holly Brogan), orthopedic surgeon (Dr.
John Kelly), the Pharmacy Department, anesthesia providers, and patients. While all key
stakeholders had an impact on the project, pharmacy and anesthesia were impacted the most. A
positive response to the addition of IV magnesium sulfate to the multimodal analgesic pathway
increased intraoperative use of magnesium sulfate, the pharmaceutical workload, and cost, both
from staff resources and the drug itself. The hope was to increase provider satisfaction of patient
care related to hip arthroscopy and reintroduce this analgesic to the community of anesthesia
providers, therefore increasing its usage for surgical patients. While the project may have longterm impact on anesthesia provider practice, the immediate outcome was to increase provider
satisfaction with patient care and consideration of IV magnesium sulfate use for analgesic
purposes.
Project Purpose
Magnesium sulfate was inconsistently utilized for multimodal analgesia at PPMC. By
adding IV magnesium sulfate as an optional adjunct to the current multimodal analgesic pathway
for hip arthroscopy patients, the project leaders hoped to increase IV magnesium sulfate use in
the perioperative setting and provider satisfaction on patient care at PPMC. The goal was to
heighten awareness of IV magnesium sulfate as a readily available and appropriate non-opioid
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analgesic adjunct. The provider’s experience and use of magnesium were evaluated through
surveys.
Conceptual and Theoretical Framework
The Plan-Do-Study-Act (PDSA) cycle was utilized in this project. The project leaders
established a plan for change, carried out the plan, observed the outcome, determined
effectiveness, and made modifications to conceive a final plan for the next cycle (Langley et al.,
1996).
Conceptual Framework
Plan
The project leaders recognized that IV magnesium sulfate is a highly effective
multimodal analgesic that is widely used in anesthesia practice but was inconsistently used at
PPMC. Patients undergoing hip arthroscopies experience high levels of pain at Penn Medicine
University City’s ambulatory surgery center, leaving anesthesia providers unsatisfied with pain
management of these cases. The project leaders hypothesized that adding an IV magnesium
sulfate bolus to the current multimodal analgesic pathway would help increase provider
satisfaction with patient care and improve its underutilization among PPMC anesthesia
providers.
Do
The project leaders informed anesthesia providers of the new IV magnesium sulfate
option to the current pathway for hip arthroscopy patients. While administration of IV
magnesium sulfate was not required by anesthesia providers, it was introduced and encouraged
as a technique to improve patient care in this surgical population. The project leaders provided a
written protocol with details regarding a recommended dosage and duration of IV magnesium
sulfate to be given to hip arthroscopy patients.
Study
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To determine the effectiveness of this intervention, the project leaders analyzed
anesthesia provider satisfaction through the Acceptability of Intervention Measure (AIM) and
overall uptake of IV magnesium sulfate by providers.
Act
The project leaders reflected on provider satisfaction, uptake of IV magnesium sulfate,
barriers to implementation, and strategies to optimize satisfaction with the process of drug
administration.
Theoretical Framework
The theoretical framework used to support the project purpose and guide clinical
decisions for reducing postoperative pain was the Middle-Range Theory of Acute Pain
Management. The Middle-Range Theory states that balancing analgesia and reducing the side
effects is the optimal goal with analgesic medications (Good, 1998). Balancing this relationship
of analgesia and symptom management aligns with the goals of the magnesium study. The
Middle-Range Theory applies to our project of treating acute pain with intraoperative
magnesium sulfate, with hopes to decrease total narcotic consumption and the undesired side
effects caused by opioids. This theory provides a conceptual basis for addressing high
postoperative pain scores in hip arthroscopy patients and supports the motive to decrease pain
scores using the synergistic effects of IV magnesium sulfate as an adjunct.
Methods
Setting
The magnesium quality improvement project was implemented at an ambulatory surgical
center located in a metropolitan area on the East Coast. This outpatient surgical center is
affiliated with a large hospital network with a great reputation for research, teaching, and
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healthcare excellence. Services provided at the surgical center included: orthopedics, general
surgery, urology, Ear Nose and Throat (ENT), gynecology, plastic, oral, and ocular plastics
surgery. Pain management services provided at this outpatient surgery center include nerve
blocks and neuraxial anesthesia.
One surgery that typically takes place at this outpatient surgical center is hip arthroscopy.
The current analgesic regimen for hip arthroscopy prior to the implementation of this project
utilized general anesthesia with a fascia iliaca block for postoperative pain management.
Standard induction doses of Fentanyl and Ketorolac before emergence were typically given,
unless contraindicated. However, there was no set regimen on intraoperative opioid
administration and its use varies among providers and patient-specific needs. PACU orders
included as-needed doses of oral oxycodone-acetaminophen and IV fentanyl for moderate to
severe pain. The regimen of a fascia iliaca block, ketorolac, and opioid administration were
multimodal attempts at treating pain in hip arthroscopy patients. However, anesthesia providers
were less liberal in opioid administration due to the ambulatory nature of this facility. This, in
addition to an incomplete nerve block, led to high levels of postoperative pain that left anesthesia
providers unsatisfied with their anesthetic management of these patients. This project was
created to determine the effects of IV magnesium sulfate on anesthesia provider utilization of
this non-opioid analgesic adjunct and satisfaction of patient care.
Participants
The participants of the project were anesthesia providers assuming intraoperative care of
hip arthroscopy patients operated on by Dr. John Kelly. They were thoroughly informed of the
added option of using IV magnesium sulfate for these cases, as discussed in the intervention
section. The use of IV magnesium was suggested and encouraged but by no means required. This
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allowed later analysis to gauge anesthesia providers’ perceptions of IV magnesium sulfate and
potentially create opportunities to refamiliarize them with magnesium’s analgesic properties that
benefit patients in opioid-sparing ways. A recommended exclusion criterion was made available
for provider reference to assist in the process of making an informed decision that is safe and
individualized for the patient. The provider would consider avoiding IV magnesium usage on the
following patients:
•

Any severe hepatic, cardiovascular, or renal dysfunctions,

•

Heart blocks

•

Neuromuscular diseases

•

Pre-existing coagulopathies

•

Known hypermagnesemia

•

Patients who are pregnant or breastfeeding

•

Currently taking calcium channel blockers, beta-blockers, or antipsychotic medications

•

Hypersensitivity to magnesium sulfate
This list was provided to anesthesia staff who wished to consider patients who may not

be proper candidates to receive IV magnesium sulfate for analgesia. However, the list was not
all-inclusive and it was made clear that it was up to providers to weigh the risks and benefits
before administration. The project took place over twelve weeks for a goal of 20 hip arthroscopy
cases where IV magnesium sulfate use was appropriate and considered.
Intervention
The multi-step intervention was divided into three phases. First, anesthesia providers
were reminded of IV magnesium sulfate’s analgesic properties and efficacy as an analgesic
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adjunct. A brief information sheet about IV magnesium sulfate with recommended dosages, an
inclusion and exclusion criterion, and team contact information was provided electronically to all
anesthesia providers at PPMC (figures 1 - 3). Additionally, anesthesia providers were
refamiliarized with IV magnesium sulfate’s utilization in multimodal analgesia and introduced to
the project during a regularly scheduled weekly staff meeting through video telecommunications.
All project team members participated in this session to promote cultural buy-in. Second, nurses
at the ambulatory surgery center were introduced to IV magnesium sulfate and its analgesic
properties through an in-person presentation of the project at their regularly scheduled staff
meeting. Two groups were educated – group one consisted of intraoperative nurses and group
two consisted of preoperative and postoperative nurses. Third, the current multimodal analgesic
pathway for Dr. John Kelly’s hip arthroscopy patients was modified to include an additional IV
magnesium sulfate option for anesthesia provider use. The decision to give IV magnesium
sulfate was made by the primary anesthesia team assuming care for the patient that day.
Information sheets were placed throughout the facility to remind staff and encourage
magnesium’s use, though care was taken not to mandate its administration. An information sheet
was posted in every operating room (OR) at the ambulatory surgery center and in the anesthesia
office at PPMC.
During project implementation, several project modifications were made to ensure
project success. To encourage provider’s participation in the project and to increase the survey
compliance, the QI project team sent a reminder email and text to providers assuming care for
Dr. John Kelly’s hip arthroscopy patients the night before and morning of respectively. Providers
were able to actively communicate with the project leads directly if concerns rose during the
implementation of IV magnesium sulfate. Instead of administering a bolus and an infusion of IV
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magnesium as outlined in the original proposal, the QI project team decided to recommend
administering a bolus of 30mg/kg with a maximum dose of 2g. The magnesium dosage
modification was made due to a request from anesthesia providers at the project implementation
site, with hopes that implementing a smaller dose of magnesium would avoid any potential side
effects, such as muscle weakness, that may delay discharge. The project leaders also suggested
administering magnesium over a minimum duration of fifteen minutes but up to one hour to
maintain hemodynamic stability and avoid potential adverse effects on blood pressure. The
project team limited the magnesium intervention to the first two hip arthroscopy cases of the day
to avoid delays in discharge from patients potentially experiencing lethargy after receiving
magnesium. Although evidence shows that lethargy after 2g of IV magnesium sulfate
administration is unlikely, this modification was made to ease anesthesia provider concerns and
improve the success rate of the project. To determine the change in magnesium usage before and
after project implementation, project leads performed a retrospective chart review for twelve
weeks before the implementation date and recorded the number of hip arthroscopy cases that
utilized magnesium. Finally, to collect more data, the project team extended our implementation
from eight to twelve weeks.
Project Implementation Plan
Phase I – Inform
Patients undergoing hip arthroscopies prior to this project received general anesthesia and
a fascia iliaca block for postoperative pain control. An IV magnesium sulfate option was added
to the standard multimodal analgesic pathway and introduced to anesthesia providers. The
project team informed anesthesia providers and perioperative staff of this change at weekly
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meetings on February 11th, 2021 and February 18th, 2021, respectively. After the meeting, the
project team sent project materials such as PowerPoint presentations used in the meetings and QI
project summary sheets, which included inclusion and exclusion criterion, magnesium dosing
guidelines, and project leads contact information (Figures 1-3). To make it easier for anesthesia
providers to participate in the QI project, the project leaders also posted reminder posters in the
operating rooms at Penn Medicine University City where the project took place (Figures 1-3).
Providers were informed of QI project protocols and the steps necessary to help implement the
project. The availability of IV magnesium sulfate was confirmed with the pharmacy department
before implementation of the project and anesthesia providers were given instructions on easily
obtaining IV magnesium sulfate from the pharmacy.
Phase II – Intervention
Patients undergoing hip arthroscopies continued to receive the current multimodal
analgesic pathway – general anesthesia and a facia iliaca block. Assuming inclusion criteria, the
anesthesia providers who elected to use the new magnesium multimodal analgesic option
administered an IV bolus of 30mg/kg or a max dosage of 2g over 30 minutes after induction of
general anesthesia. All patients continued to receive a fascia iliaca block before emergence. The
magnesium intervention is visually displayed within a process flow chart (Figure 4).
Phase III – Data collection
After twelve weeks of project implementation, provider satisfaction of patient care was
measured using Research Electronic Data Capture (REDCap) survey distributed electronically.
Anesthesia providers accessed and completed this survey in one of two ways, either through a
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QR code or a link in the emails they received. Usefulness and satisfaction of the magnesium
practice change were then determined through analysis of provider surveys. To determine
whether the project had an impact on increasing magnesium usage, the project leaders conducted
retrospective electronic chart reviews collecting data on the number of Dr. Kelly’s hip
arthroscopy cases in which IV magnesium sulfate was used twelve weeks before project
implementation and twelve weeks after project implementation.
Measures
To evaluate the success of our implementation plan, the project leaders measured
anesthesia provider’s overall uptake of magnesium sulfate use in the perioperative setting, and
satisfaction of patient care via an electronic survey. To assess provider’s satisfaction with the
addition of the magnesium option, the project leaders used the AIM developed by Weiner et al.
(2017). AIM is a four-item measurement of implementation outcomes that is used to assess the
stakeholder's acceptability of an implementation (Figure 5). AIM asked anesthesia providers to
rate each of the following four items on a 1 to 5 scale. The Response Scale was identified as: 1 =
Completely disagree; 2 = Somewhat disagree; 3 = Neither agree nor disagree; 4 = Somewhat
agree; and 5 = Completely agree.
1.

The IV magnesium option meets my approval.

2.

The IV magnesium option is appealing to me.

3.

I like the IV magnesium option.

4.

I welcome the IV magnesium option.
All anesthesia providers who provided intraoperative care for Dr. Kelly’s hip arthroscopy

procedures were given these surveys to assess changes in provider satisfaction upon introducing
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the magnesium option to the standard multimodal analgesic pathway (Figure 5). Follow-up
emails were sent weekly to ensure a high response rate.
The project leaders also conducted an electronic chart review on Dr. Kelly’s hip
arthroscopy patients, twelve weeks before and twelve weeks after the project implementation
date. The data recorded included the date of the case and whether magnesium was used. A run
chart displaying the overall trend in magnesium usage pre-intervention and post-intervention
weekly was plotted and analyzed.
Data Management Plan
Data was collected and managed using REDCap. REDCap is a software application for
secure data management and collection. To ensure data security, data collected to analyze
magnesium use was un-identifiable and was conducted via retrospective chart reviews. Data
collected to determine anesthesia provider satisfaction was distributed via a REDCap survey and
remained identifiable. Access to REDCap project data was granted only to the project team (Dr.
Ignacio Badiola, Julianne Bagley, Naomi Song, and Erica Yi). The data collected will remain in
the REDCap application to ensure secure long-term storage.
In preparation for data analysis, several strategies were employed to ensure the efficiency
and accuracy of data collection. First, a project log was created within Basecamp, a project
management system, to document problems that arose and decisions that were made. Project
leaders tracked responses and ensured accurate project implementation weekly via Basecamp. A
data codebook was created to include the label for each data item and the level of measurement.
Efficient and accurate data collection was possible through open and documented
communication, frequent project participant monitoring, and a clean data codebook.
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Analysis

After project implementation was completed, the data was cleaned to prepare for
analysis. Missing responses to questions were removed prior to analysis. The cleaned data was
analyzed using descriptive statistics. Absolute frequencies (counts) and relative frequencies
(percentages) were used to summarize provider satisfaction with the added option of IV
magnesium sulfate to the multimodal analgesic pathway. To assess the relationship between
adding IV magnesium sulfate to the multimodal pathway (the independent variable) and actual
utilization of IV magnesium sulfate by anesthesia providers, a run-chart was created. Pre- and
post- implementation rates of magnesium use for hip arthroscopy patients were determined and
plotted on a line graph. Clinical significance was defined as a 50% increase in IV magnesium
sulfate administration in this patient population.
Ethical Considerations
This project was acknowledged as a quality improvement initiative by the International
Review Board (IRB) of the University of Pennsylvania. There are no financial disclosures.
Results
Over the twelve weeks of implementation phase, ten CRNAs were involved in the
anesthetic care of fourteen hip arthroscopy cases by Dr. Kelly and eight CRNAs (respondents)
participated in the project survey. Among the two non-respondents, one CRNA opted for the
magnesium option but did not respond to the survey while one did not use magnesium at all. A
satisfaction survey was not filled out by this provider and no insights were gained as to why the
option was not used.
In the AIM survey, 71% (5/7) CRNAs rated at least somewhat agree to “IV magnesium
sulfate meets my approval”, and one participating CRNA left this item blank. A total of 75%
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(6/8) CRNAs rated at least somewhat agree to “the IV magnesium option is appealing to me”.
75% (6/8) rated at least somewhat agree to “I like the IV magnesium option” and 75% (6/8) rated
at least somewhat agree to “I welcome the IV magnesium option (Figure 6a).
100% of participating CRNAs (8/8) reported that their decision to use magnesium was
influenced by the QI initiative and would consider using IV magnesium in future practice (Figure
6b). Seven out of seven CRNAs (100%) were satisfied with the QI initiative, and one CRNA left
this question blank (Figure 6b).
Comments made by the participating CRNAs regarding their observations of the
intraoperative magnesium use on patient care included “smooth emergence” and “patient woke
up very comfortable”. Two CRNAs noted “no changes”.
Twelve weeks prior to project implementation, zero out of eighteen hip arthroscopy
patients received IV magnesium. With project implementation, twelve out of the fourteen hip
arthroscopy patients over a twelve-week period received IV magnesium, yielding an 85.7%
increase in IV magnesium utilization. A run chart displaying biweekly rates of IV magnesium
utilization before and after this QI initiative was plotted (Figure 7).

Discussion
Summary of Findings
After project implementation, there was an 85.7% increase in IV magnesium utilization
for eligible hip arthroscopy patients. Nine out of ten (90%) CRNAs who took care of hip
arthroscopy patients used IV magnesium sulfate over a twelve-week project implementation
period. 100% of survey respondents reported being satisfied with patient care after incorporating
IV magnesium sulfate to their anesthetic plan and would consider using it in future practice.
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Interpretation of Project Results
IV magnesium sulfate had the potential to mitigate the problem of high pain levels but
was found to be scarcely used among anesthesia providers at this institution. By adding IV
magnesium sulfate as an optional adjunct to the current multimodal analgesic pathway for hip
arthroscopy patients, the project leaders hoped to increase IV magnesium sulfate usage in the
perioperative setting and anesthesia provider satisfaction of patient care at PPMC.
The 85.7% increase in magnesium sulfate utilization post-implementation suggested
effectiveness of this QI initiative in increasing magnesium usage at PPMC. In fact, 100% of
CRNAs that responded to the project survey stated that they would consider using IV magnesium
in their future practice. This project helped demonstrate that IV magnesium sulfate is a readily
available and appropriate non-opioid analgesic adjunct for surgical patients.
During weeks 5 and 6 of project implementation, there were no hip arthroscopy cases
performed at the ambulatory surgery center. IV magnesium sulfate use dropped to 0% as a result
of the lack of opportunity for utilization (Figure 6a). Therefore, the steep decline in IV
magnesium utilization during these weeks was not clinically significant.
The project team found overall positive responses to IV magnesium sulfate and its
implication on patient care. Many anesthesia providers were willing to consider its use in future
practice, apart from this project initiative. Increased utilization of IV magnesium sulfate has
multifactorial benefits. IV magnesium is less costly than opioids, which decreases costs to the
patient and hospital. The anesthesia provider’s challenge in achieving adequate analgesia is
addressed by the non-opioid properties of IV magnesium. Use of IV magnesium through this
project initiative may inspire these CRNAs to administer magnesium in other settings where they
provide anesthetic care and help promote its use among the anesthesia community at PPMC.
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Limitations
Several limitations should be considered when interpreting the results of this project. The
number of hip arthroscopy cases at the ambulatory surgery center was far less than expected. The
limited number of participants could be due to a smaller volume of surgical cases performed
during the COVID-19 pandemic. As a result, the project leaders cannot exclude the possibility of
false statistical significance. Finally, the limited nature of interpersonal interaction and
challenges of virtual meetings during the pandemic could have negatively impacted cultural buyin.
Conclusion
It was found that patients undergoing hip arthroscopy at PMUC experienced high levels
of postoperative pain. IV magnesium sulfate has been shown to be an effective analgesic adjunct
that could help decrease postoperative pain without the adverse effects seen with opioid
administration. An organizational assessment and analysis of CRNA experiences in anesthetic
practice led to this QI initiative. The addition of IV magnesium sulfate to the current multimodal
analgesic pathway for Dr. Kelly’s hip arthroscopy patients resulted in an increase of 85.7% in IV
magnesium. 100% of anesthesia providers who administered IV magnesium were satisfied with
patient care as a result of this project implementation. The goal of increasing IV magnesium use
as a non-opioid analgesic adjunct among anesthesia providers and improving patient care
satisfaction was achieved.
Sustainability Plan
After project implementation, conclusion, and dissemination of the results, the successes
and failures of the project were evaluated using the PDSA framework and the Middle-Range
Theory of Acute Pain Management.
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The analgesic effects of magnesium are high yield for the patient, the anesthesia provider,
and the hospital. Magnesium is an abundant and inexpensive medication that has shown great
success in decreasing pain scores and opioid consumption, which leads to improved patient and
provider satisfaction. Magnesium is not only easy for providers to use, but also inflicts fewer
side effects that would be seen with opioid use. Magnesium's intraoperative use is likely to be
sustained after project termination. Open communication with key stakeholders about the project
is important for long-term sustainability and therefore a reassessment of buy-in from key
stakeholders is necessary. Project results were shared with key stakeholders. Through proper
evaluation of the project and maintenance of open communication, the utilization of magnesium
sulfate as an analgesic adjunct will likely increase. Communication with stakeholders will take
place on-site or through virtual platforms depending on the trajectory of COVID-19 and evolving
changes to Centers for Disease Control and Prevention (CDC) guidelines.
Implications for Practice
Magnesium is widely used in anesthesia practice as a multimodal analgesic but is
infrequently utilized at Penn Presbyterian Medical Center. The multimodal analgesic pathway for
hip arthroscopy patients did not incorporate magnesium sulfate prior to the implementation of
this project. This quality improvement project incorporated the latest evidence and addressed the
gap in magnesium utilization by refamiliarizing anesthesia providers with magnesium’s
analgesic properties. Re-introducing anesthesia staff to the analgesic components of IV
magnesium sulfate creates a culture that utilizes magnesium readily and appropriately as a nonopioid analgesic adjunct. This project targeted a specific population, but the intervention of an IV
magnesium sulfate bolus is easily transferrable to various surgical procedures. It is our hope that
this project helped incorporate IV magnesium sulfate as an analgesic adjunct for anesthesia
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providers to consider in their daily anesthetic practice. Experiencing the effectiveness of IV
magnesium sulfate widens the range of analgesic options available to anesthesia providers and
facilitates practice change with beneficial outcomes.
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Figure 4
Process Flow Chart
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Note. Anesthetic management with QI initiative option added to the multimodal pain pathway for
Dr. Kelly’s hip arthroscopy patients at Penn Medicine University City Ambulatory Surgery
Center.
Figure 5
AIM Survey & Satisfaction Survey
Rate each of the following four items on a 1 to 5 scale.
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Note. Post-implementation magnesium survey distributed to anesthesia providers to assess
satisfaction with patient care using AIM (questions 1-4) and magnesium use.
Figure 6
6a. AIM Survey Results
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Note. AIM Survey and Satisfaction Results display the frequencies of each magnesium
satisfaction score from anesthesia providers.
6b. Magnesium Uptake, Future usage and Satisfaction

37

MAGNESIUM UTILIZATION IN HIP ARTHROSCOPY

Figure 7
Magnesium Use Run Chart

Note. Rate of IV magnesium sulfate usage by anesthesia providers over 8 weeks preimplementation and 12 weeks post-implementation.
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Table
Table 1
Synthesized Table of Evidence
Citation

Surgical
Sample

Dehkordy et Posterior
al., 2020
lumbar
surgery
El Mourad
Lap. Sleeve
et al., 2020
gastrectomy
Gucyetmez
et al., 2016
Jarahzadeh
et al., 2016

Liver
Transplant
TAH

Mireskandar
i et al., 2015
Sahar et al.,
2017
Shah et al.,
2016

Cesarean
Section
Arthroscopi
c knee
Lower
abdominal/l
ower limb
surgery
TKA

Shin et al.,
2016
Sohn et al.,
2017

VATS

Anesthetic,
ASA class

Intra-op Magnesium
Treatment
Bolus
Infusion

Sample Size Post-op
(n)
evaluation
time (t)

Post-op Outcome Measures
↓ pain
scores

↓ analgesic
requirements
+

+

+

GA, ASA 1-2

+

+

N = 120

48 hours

GA, ASA 1-2

+

+

N = 120

24 hours

GA

+

N = 70

24 hours

GA, ASA 1-2

+

N = 60

12 hours

+

+

GA, ASA 1-2

+

N = 50

24 hours

+

+

Epidural,
ASA I-2
Spinal, ASA
1-2

+

+

N = 70

24 hours

+

+

+

+

N = 108

24 hours

+

+

Spinal, ASA
1-2
GA

+

+

N = 44

48 hours

+

+

+

+

N = 66

48 hours

+

+
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Taheri et al., TAH
2015

GA, ASA 1-2

40

+

N = 40

24 hours

+

+

Note: IV magnesium sulfate bolus and/or infusion given in various surgical procedures show a decrease in postoperative pain scores
and analgesic requirements twenty-four to forty-eight hours after.
ASA = American Society of Anesthesiologist; GA = General Anesthesia; TAH = Total Abdominal Hysterectomy; TKA = Total Knee
Arthroplasty; VATS = Video-Assisted Thoracoscopic Surgery.
Table 2
Table of Evidence
Citation or
Study No.
Dehkordy et
al., 2020

Research
Aim,
Question,
Hypothesis
This study
hypothesize
d that
magnesium
sulfate
administrati
on will
reduce
postoperativ
e pain.

Setting,
Sample, and
Sampling

Design

Variables
and
Measures

Findings

Critique

Level of
Evidence

Conclusions

Randomized
doubleblind
parallelcontrolled
clinical trial
conducted
in Shohada
Tajrish
training
hospital in
2018-2019.
120 patients
assessed for
eligibility

Pts were
randomly
divided into
2 groups.
Exposure
was
50mg/kg
bolus of
magnesium
sulfate in
100mL
saline over
15 min prior
to induction,
followed

Control:
50mg/kg
bolus of
isotonic
saline
followed by
continuous
15mg/kg/h
infusion
during
operation.

Significant:
PCA
morphine
consumptio
n at 6, 12,
24, 48 hrs
postoperativ
e lower in
magnesium
group;
lower rate
of rescue
analgesic
request from

Strengths:
Large
sample size
RCT study
design

1B

Perioperativ
e IV
magnesium
administrati
on improves
postoperativ
e analgesia,
decreases
morphine
consumptio
n.

Experiment
al: 50mg/kg
bolus of

Weaknesses
: Literature
showed
varying
results.
No clear
conclusion
based on
paucity of

MAGNESIUM UTILIZATION IN HIP ARTHROSCOPY

El Mourad
et al., 2020

(20-80 years
old) ASA 12 who
underwent
posterior
lumbar
surgery.
After
exclusion,
N=80 for
randomizati
on. Sample
size was
divided into
two (n=40)
groups.
Study
Randomized
hypothesize controlled
d that IV or doubleIP
blind study
magnesium from
sulphate
Januarywill reduce
May 2018.
the
N=120 aged
hemodynam 18-60 years
ic stress
with
response to BMI>35
pneumoperit kg/m2 and
oneum and
ASA I-II
provide
enrolled.
improved
pain control
after

41

with
continuous
15mg/kg/h
infusion
during
operation.

magnesium
sulfate over
15 min prior
to induction,
followed by
continuous
15mg/kg/h
infusion
during
operation.
VAS
assessed
prior to and
post
operation.

the control
group.

3 groups
(n=40 each).
Exposure
was either
100mL
30mg/kg IV
MgSO4 or
30mL of IP
MgSO4.

Control:
Group C:
100mL of
0.9% NS
over 10min
with 30mL
NS IP

Significant:
MAP and
HR lower
from T3 to
T8 in group
I > P > C.
Pain scores
highest in
group C > I
> P 2hrs
postoperativ
ely.

Experiment
al: Group I:
100mL of
30mg/kg
MgSO4
with IP
instillation

Nonsignificant:
Intraoperati
ve blood
loss.

Lower VAS
score in
group P, no
significant

data and
controversia
l
conclusions
from
systematic
reviews.

Strengths:
RCT study
design
Large
sample size
Ease of
replicability.
Weaknesses
:
Scarce data
on
magnesium
dosing in
obese
patients.
Reputability
and

1B

30mg/kg of
MgSo4 IV
or IP are
effective
adjuncts that
blunts
sympathetic
stress
response to
pneumoperit
oneum and
decreases
postoperativ
e pain
scores and
analgesic
consumptio
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laparoscopic
sleeve
gastrectomy
.

Gucyetmez
et al., 2016

The study
hypothesize
d IV
MgSO4
reduces
postoperativ
e tramadol
requirement
in liver
transplant
patients.

42
of 30mL of
0.9% NS
Group P:
100mL
0.9% NS
over 10 min
with 30mL
of 30mg/kg
IP MgSO4

Randomized
double
blind, N=70
from
October
2014 to
April 2015,
age > 18yrs
old with
operation
duration of
10-12hrs
and
clamping
duration of

N=70
divided into
two groups
(experiment
al group
with
baseline
serum mag
<1.8; and
control
group
baseline
serum mag
>1.8).
Exposure

Experiment
al: 50mg/kg
IV MgSO4
in the last
30min of
surgery.
Control:
same
volume of
NS.
Measure:
Patient's
age, sex,

difference
between
group C and
I (P=0.070).
Nonsignific
ant:
No variation
in VAS
score
amongst all
groups at 8,
12, 24h
postoperativ
e (P=0.194,
0.117, 0.193
respectively
).
Significant:
the
magnesium
group had
lower mean
24-hr total
tramadol
requirement,
duration of
MV and
longer 1st
tramadol
timing
(P<0.001)

evidence
grade of
using IBW
for dosing
unknown.

Strength:
Findings in
this study
are
consistent
with other
studies;
project
leaders also
divided up
the groups
by its
baseline
serum
magnesium

n in the
immediate
postoperativ
e period up
to 4 hours in
obese
patients
undergoing
LSG.

1B

Intraoperati
ve use of IV
MgSO4 in
liver
transplantati
on reduces
the need for
postoperativ
e tramadol
and MV.
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<80min
were
included in
the study.

Jarahzadeh
et al., 2016

Study
hypothesize
d
magnesium
sulphate
administrati
on will
reduce
postoperativ
e pain and
narcotic
requirement
after
abdominal
hysterectom
ies.

Doubleblind,
randomized
clinical trial
in Shahid
Sadoughi
Hospital in
Iran from
2013 to
2015 with
N=60. Pts
age 35-65
years old,
ASA I-II.

was
50mg/kgIV
MgSO4 in
the last
30min of
surgery. All
patients
received
standard
anesthesia
induction,
and
maintenance
Two groups
of n=30
each.
Exposure
was
50mg/kg
magnesium
sulfate in
500cm3 of
Ringer's
serum over
20 minutes.

43
BMI,
MELD,
APACHE II
scores, MV,
LOS-ICU,
LOShospital,
24hr total
tramadol
requirement
and time of
1st tramadol
need were
recorded
All groups
received
5mg
morphine
30min after
induction of
anesthesia.
Control:
500 cm3 of
Ringer's
serum
Experiment
al:
50mg/kg
MgSO4 in
500cm3 of
Ringer's

Nonsignificant:
age, sex,
BMI,
operation
duration,
MELD,
APACHE
II. LOSICU, LOShospital
were
comparable

level that
made the
effect of
magnesium
more
significant
between two
groups.

Significant:
Pain scores
lower in
experimenta
l group at all
time
intervals up
to 6hrs after
surgery.
Control
group
required
more rescue
opioids.

Strengths:
High level
of study
design.

Weakness:
small
sample size

Weakness:
No
differentiati
on in BSA
was
accounted
for when
administerin
g narcotics.
All patients
received the
same dosage
of
midazolam

1B

50mg/kg
intraoperati
ve IV
magnesium
sulfate
administrati
on
significantly
decreases
postoperativ
e pain and
reduces
morphine
consumptio
n after
abdominal
hysterectom
y.
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serum over
20 min.
VAS scores
were
assessed in
the
immediate
postoperativ
e period,
then at 1, 2,
6, and 12
hours after
surgery.

Mireskandar This study
i et al., 2015 hypothesize
d IV
MgSO4
decrease
postcesarean
pain and
opioid
requirement
during first
24hours.

Double
blind
randomized
clinical trial
occurred at
Tehran
University
of medical
sciences.
N=50, ASA
I and II
scheduled
for elective
C/S

N=50
divided up
to two
groups.
Exposure in
the
experimenta
l group was
50mg/kg IV
MgSO4
infused
within
15min prior
general
anesthesia

Experiment
al: 50mg/kg
IV MgSO4
made in
500ml NS
infused
within
15min prior
general
anesthesia
Control:
500ml NS
Measure:
VAS within
24hrs after
C/S; and

Significant:
mag group
has lower
VAS scores
at 1, 6, 12th
hours after
c/s
(p<0.001,
0.002, 0.05
respectively
), and lower
morphine
usage
during
24hours
(p<0.001)

and
morphine as
opposed to a
weightbased dose.
Small
sample size
and rather
narrow age
range for
inclusion
criteria was
utilized
without
explanation.
Strength:
1B
high level of
study
design, and
relate
findings to
other similar
studies
Weakness:
small
sample size

Magnesium
administrati
on
immediately
prior to
induction of
general
anesthesia
decrease
VAS score,
as well as
postop
morphine
requirement
during the
first
24hours.
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Sahar et al.,
2017

This study
hypothesize
d IV
MgSO4
infusion
attenuate
TIH and
tourniquet
pain and
also reduce
postop
analgesia
requirement
in patients
undergoing
arthroscopic
knee
surgery
under
epidural
anesthesia

Randomized
, double
blind
controlled
study,
N=70, ASA
I and II (age
20-60 years)
undergoing
arthroscopic
knee
surgery with
tourniquet
under
epidural
anesthesia.

N=70,
n=35.
Exposure
was IV
MgSO4
bolus
30mg/kg in
50ml NS
over 10min,
followed by
infusion
10mg/kg/h.
IV fentanyl
was given if
needed.
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morphine
usage
during 24hrs
postoperativ
ely
Experiment
al: IV
MgSO4
bolus
30mg/kg in
50ml NS
over 10min,
followed by
infusion
10mg/kg/h
Control:
same
volume of
NS for
bolus and
infusion.
Measure:
SBP, DBP,
HR were
measured at
baseline,
after
epidural,
and every
10min after
tourniquet

Nonsignificant:
VAS at
24hrs
Significant:
patients in
the
experimenta
l group had
lower SBP,
DBP, HR
(p<0.001)
after 50min
of inflation,
less TIH
and lower
VAS score
for
tourniquet
pain
(p<0.05),
longer time
to feel pain
(p<0.001),
lower
intraoperati
ve fentanyl
requirement
(p<0.001),
with higher
serum mag
level at 6h

Strength:
The study
was clear on
their
inclusion
and
exclusion
criteria and
project
leaders used
multiple
measures at
multiple
time points
when
analyzing
the effect of
magnesium
on pain and
its
intraoperati
ve benefits
Weakness:
VAS was
not assessed
with
movement

1B

In patients
undergoing
arthroscopic
knee
surgery
under
epidural
anesthesia,
IV MgSO4
in a dose of
30 mg/kg,
followed by
10 mg/kg/h
infused
before
tourniquet
inflation
could
reduce TIH,
and
tourniquet
pain with
reduction in
intraoperati
ve IV
fentanyl and
postoperativ
e pethidine
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inflation,
and 1, 5, 10
and 30min
after
deflation,
tourniquet
pain, and
total IV
fentanyl
consumptio
n. VAS was
assessed at
1, 2, 4, 8,
12, 18 and
24 hours,
postop
pethidine
consumptio
n was
recorded,
and serum
mag was
measured
preop and at
6 and 24hr
postop.

Shah et al.,
2016

The
hypothesis
of the RCT
is the
increase of
analgesic

Prospective
randomized
control trial,
doubleblinded
study with

Two groups
of n = 54
each. The
exposure
was a
magnesium

Experiment
al group:
received
250mg IV
magnesium
bolus,

postoperativ
e (p<0.001),
and had
lower
postoperativ
e pethidine
dose.
Nonsignificant:
maximal
dermatome
achieved by
epidural,
and sensory
and motor
block were
the
comparable
between two
groups.
VAS score
after 18 and
24h, as well
as PONV
were
comparable.
Statistically
significant:
VAS scores
immediately
post-op (p =
0.006) and

and sample
size was
small

Strengths:
large sample
size and
generalizabi
lity to adult
patients

requirement
s.

1A

250 mg
magnesium
bolus
followed by
20mL/hr
infusion

MAGNESIUM UTILIZATION IN HIP ARTHROSCOPY
effects and
duration of
sensory/mot
or blockade
of I.V.
magnesium
during
spinal
anesthesia.
Study also
analyzed
hemodynam
ic effects of
magnesium
and the
analgesic
requirement
s after
surgery.

N = 108
patients
undergoing
lower
abdominal
and lower
limb surgery
with spinal
anesthesia.
ASA I and
II, 18-65
years of age,
and height
within 150180 cm.

bolus of
250mg IV,
followed by
an infusion
of 20mL/hr.
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followed by
an infusion
of 20mL/hr.
Control
group:
received the
same
volume as
magnesium
group, but
with normal
saline.
Post-op
pain
assessed
with VAS,
rating pain
1-10.
Rescue
analgesia
given when
pain score
above 3.
Sensory
blockade
time
recorded
when
sensory
block
regression

at the 4hour
interval (p =
0.001)
decreased in
the
experimenta
l group.
Sensory
blockade
increased
about 25
minutes and
motor
blockade
increase of
about 34
minutes in
experimenta
l group (p =
0.001).
Number of
rescue
analgesic
requirement
s decreased
in the
experimenta
l group (p =
0.009)

undergoing
surgery with
spinal
anesthesia.
Weaknesses
: no
differentiati
on of
analgesic
requirement
s, sensory
blockade,
and motor
blockade
between
magnesium
group and
longer
spinal
blockade.

significantly
decreases
VAS scores
immediately
post-op and
within 4
hours,
increases
sensory and
motor
blockade,
And
decreases
post-op
rescue
analgesic
requirement
s.
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Shin et al.,
2016

Study
hypothesize
d
magnesium
can reduce
post-op pain
scores and
intensity for
patients
undergoing
the second
of a staged
bilateral
TKA,
occurring
one week
after the
first
surgery.

Randomized
double
blinded
control trial.
Conducted
at Seol
National
University
Bundang
Hospital
from March
to
December
2015. N =
44 patients
undergoing
staged
bilateral
TKA under

Two
groups of
n=22 each.
The
exposure
was a
50mg/kg
magnesium
bolus over
15 minutes,
followed by
a
15mg/kg/hr
infusion of
magnesium
for the
remainder
of the
surgery.
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to L1, and
motor
blockade
time
recorded
when knee
flexion
recovered.
Heart rate
and blood
pressure
measured
every 4
hours.
All patients
received
pre-op
Midazolam,
femoral
nerve block,
and spinal
anesthesia.
Experiment
al group:
received
50mg/kg of
magnesium
over 15
minutes,
followed by
infusion of
15mg/kg/hr

Statistically
significant:
VAS scores
higher in
control
group
compared to
experimenta
l group after
the first
TKA (p =
0.001) and
after the
second TKA
(p =
<0.001). In
the control
group VAS
scores

Strengths:
high level of
study design
(double
blinded
RCT) and
the
reproducibil
ity of the
study
described.
Weaknesses
: majority
of the study
population
were elderly
females.

1B

Magnesium
successfully
decreased
VAS scores
and
analgesic
requirement
s despite an
increase in
pain
intensity
with the
second
surgery of a
staged
bilateral
TKA.
Magnesium
may be
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spinal
anesthesia,
ages 50-80
years, and
ASA I and
II.
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for the
remainder
of the
surgery.
Control
group:
received the
same
volume as
the
experimenta
l group, but
in isotonic
solution.
VAS used
to assess
post-op pain
scores
ranging
from 0-100
at the 24
and 48 hour
time
interval.
Rescue
analgesic
and PCA
use assessed
at the 24
and 48 hour

increased at
24 hours (p
= <0.001)
and 48
hours (p =
0.006) postop and PCA
requirement
s increased
after the
second TKA
(p = 0.011)
surgery
compared to
the first (p =
0.004).
Nonsignificant:
In the
experimenta
l group
VAS scores
did not
increase
significantly
between the
first TKA
and the
second at 24
hours (p =
0.480) and
48 hours (p

Pain
determined
by VAS
score
instead of
quantitative
sensory
testing
(QST). Pain
only
assessed at
rest because
of increased
pain
intensity
with
mobilization
.

successful at
controlling
increased
pain caused
by multiple
surgeries
with
increased
intensity.
May
decreased
chronic pain
due to its
effects to
decrease
post-op
analgesic
requirement
s.
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Sohn et al.,
2017

This study
hypothesize
d IV
MgSO4
help
improve
PFT results,
reduce
muscle
relaxant
requirement,
and PCA
requirement
after videoassisted
thoracoscop
ic surgery

Taheri et al., The study
2015
hypothesize
d a single
bolus of

Randomized
doubleblind
occurred in
a university
tertiary care
center,
N=66, 2575 years
old,
thoracoscop
ic surgery of
segmentecto
my or
lobectomy,
tracheal
extubation
in the OR,
and postop
pain
managemen
t using
PCA.

N=66
divided into
2 groups.
Exposure
was IV Mag
50mg/kg for
10 min
followed by
a continuous
infusion of
15mg/kg/hr
during
surgery

Double
blinded,
randomized
placebo

Two groups
of n= 20
each. The
exposure

50
time
intervals.
Experiment
al: IV Mag
50mg/kg for
10 min
followed by
a continuous
infusion of
15mg/kg/hr
Control:
same
volume of
NS bolus
and
infusion.
Measure:
PFT: at
preop,
postop at 2,
24, and 48h;
total usage
of muscle
relaxant;
total PCA
consumptio
n
Experiment
al group:
received a
50mg/kg in

= 0.378)
post-op.
Statistical
significant:
FEV1 and
FVC are
greater in
the
magnesium
group
postop 24
and 48
hours.
Mag group
required less
rocuronium,
and lower
PCA
consumptio
n.
Nonsignificant:
FEV1 and
FVC at 12
months after
surgery
Statistically
significant:
Post-op pain
scores

Strength:
RCT design

1B

Intraoperati
ve IV
MgSO4
improved
PFT and
reduced the
need for
muscle
relaxant
and PCA
requirement
under video
assisted
thoracoscop
ic surgery.

1B

Magnesium
bolus of
50mg/kg is
effective in

Weakness:
small
sample size,
and
project
leaders did
not measure
mag
concentratio
n
postoperativ
ely, which
could
affected the
post
analgesia
needs.

Strengths:
high level of
study design
(double
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magnesium
sulfate will
lower postop pain
scores
following a
TAH under
general
anesthesia.

trial. Study
took place
at the
OBGYN
ward at AlZahra
Maternity
Hospital in
Rasht from
May 2013
to May
2014. N =
40 women
having a
TAH with
general
anesthesia,
ASA I or II.

was a
50mg/kg
magnesium
bolus in
100mL of
NS prior to
induction of
anesthesia.
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100mL
bolus of
magnesium
sulfate 15
minutes
prior to
induction.
Control
group:
received an
100 mL of
NS.
Demerol
consumptio
n and NRS
evaluated at
0, 6, 12, and
24 hour
time
intervals
post-op.

lower in the
experimenta
l group at
the 6, 12,
and 24 hour
time interval
after surgery
(p<0.05).
Demerol
requirement
was lower
in the
experimenta
l group
throughout
the whole
24 hour
post-op
period (p =
0.0001).
Nonsignificant:
post-op pain
scores at the
time of
emergence.

blinded
RCT),
addressing
previous
study
limitations,
and
acknowledg
ement of no
funding
conflicts of
interest.

lowering
pain scores
at 6, 12, and
24 hour
post-op and
decreasing
opioid
consumptio
n in patients
undergoing
general
anesthesia.

Weaknesses
: not
determining
serum
ionized
magnesium
and the
small
sample size
of the study
may not be
representati
ve of the
population
as a whole.

Note: Level of evidence of ten studies evaluating IV magnesium sulfate.
APACHE = Acute Physiology and Chronic Health Evaluation; ASA = American Society of Anesthesiologist; BMI = body mass
index; C/S = cesarean section; IP = Intraperitoneal; IV = Intravenous; LOS-hospital = length of hospital stay; LOS-ICU = length of
intensive care unit stay; MELD = Model for End-Stage Liver Disease; MgSO4 = Magnesium Sulfate; MV = duration of mechanical
ventilation; NRS = Numeric Rating Scale; NS = Normal Saline; PFT = pulmonary function test; PONV = postoperative nausea and
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vomiting; TAH = Total Abdominal Hysterectomy; TIH = tourniquet induced hypertension; TKA = Total Knee Arthroplasty; VAS =
Visual Analog Scale.
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Appendix A
DNP Team and Project Implementation Form
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Appendix B
Project Charter

AIM
Magnesium sulfate is inconsistently utilized for multimodal analgesia at Penn Presbyterian
Medical Center (PPMC). By adding the option to include IV magnesium sulfate to the current
multimodal analgesic pathway for hip arthroscopy patients, the project leaders hope to inspire
practice change of increasing magnesium sulfate use. The purpose of our quality improvement
project is to inform and refamiliarize anesthesia providers with magnesium sulfate's
multimodal analgesic properties, and to increase IV magnesium sulfate use in the perioperative
setting and provider satisfaction of patient care.
PROBLEM
Hip arthroscopy patients experience high levels of postoperative pain, leading to higher pain
scores, increased rescue analgesic consumption, and decreased patient satisfaction.
Magnesium sulfate is widely used in anesthesia practice as a multimodal analgesic but is
underutilized at Penn Presbyterian Medical Center. Does adding the option of IV magnesium
sulfate to the current multimodal analgesic pathway increase magnesium use and provider
satisfaction of patient care?
IMPORTANCE
Magnesium has demonstrated to be an effective multimodal analgesic agent and is a low-cost
agent but is infrequently utilized at PPMC. This magnesium quality improvement project
serves as a re-introduction to the PPMC anesthesia staff to the possibilities of IV magnesium
sulfate as an analgesic adjunct for many surgical procedures and create a culture that utilizes
magnesium readily and appropriately as a non-opioid analgesic adjunct. If magnesium is used
effectively, it can facilitate practice change among anesthesia providers regarding analgesic
options for patient care.
EXPECTED OUTCOMES
For anesthesia providers taking care of patients undergoing hip arthroscopy operated on by Dr.
John Kelly at the Ambulatory Surgery Center in University City. A target of 20 anesthesia
providers will be met in a 12-week implementation phase.
1. 50% will receive a bolus and continuous infusion of IV magnesium sulfate on a
weight-based dose.
2. 50% anesthesia providers express satisfaction on patient care after adding magnesium
to the current analgesic pathway
3. 50% anesthesia provider accepts this practice change and will consider magnesium in
future practice
MEASURES
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A REDCap survey will be distributed electronically to assess anesthesia provider’s overall
uptake of IV magnesium administration in the new multimodal analgesic pathway, as well as
satisfaction on patient care. The Acceptability of Intervention Measure (AIM) will ask
anesthesia providers to rate each of the following four items on a 1 to 5 scale. The Response
Scale will be identified as: 1 = Completely disagree; 2 = Somewhat disagree; 3 = Neither agree
nor disagree; 4 = Somewhat agree; and 5 = Completely agree.
1. The IV magnesium option meets my approval.
2. The IV magnesium option is appealing to me.
3. I like the IV magnesium option.
4. I welcome the IV magnesium option.
Additional questions will be added to AIM to assess provider’s overall uptake on magnesium
use after our implementation.
1. Have you consistently used IV magnesium as an analgesic adjunct in your anesthetic
practice previously? Yes or no
2. Did you use magnesium for this case? Yes or no
3. Was your decision to use magnesium for this case influenced by the updated multimodal
analgesic pathway highlighted by this quality improvement project? Yes or no, I have
always considered magnesium in my practice.
4. Are you likely to consider using IV magnesium in your practice in the future? Yes or no
5. Are you satisfied with your patient care as a result of this QI initiative? Yes or no.
RISKS/BARRIERS
While research has displayed magnesium to be an effective analgesic adjunct, the project site
inconsistently utilizes magnesium currently as an analgesic adjunct. Staff buy-in is a potential
barrier to success of the magnesium quality improvement project.
STAKEHOLDERS
The stakeholders of this project will be Dr. Mark Pizzini (Director of Anesthesia), Edward
Czerpak (Chief CRNA), Dr. Ignacio Badiola (Site Lead), pharmacists, CRNAs and PACU
nursing team at the project site. Successful implementation of the project will require buy-in
from key stakeholders, and therefore information on the purpose and detailed intervention
measure will be distributed among the key stakeholders and issues and concerns will be
followed up by the project leads via email and in-person interaction, as allowed, on a weekly
basis. Patient improvement will be analyzed through weekly chart reviews of pain scores and
opioid consumption to ensure the patient experience is satisfactory.
SCOPE
In Scope:
Out of Scope:
Anesthesia providers providing care for patients who Anesthesia providers who are not
are age >18 years, ASA I-II, patients undergoing hip participating in anesthetic management
arthroscopy procedures with general anesthesia and
and patient care for these case types.
fascia iliaca block, operated on by Dr. John Kelly
SCHEDULE
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Project implementation will begin in February 2021 for 12 weeks.
PROJECT TEAM
Julianne Bagley, SRNA
Naomi Song, SRNA
Erica Yi, SRNA
Dr. Ignacio Badiola
Dr. Holly Brogan

Lead
Lead
Lead
Site lead
DNP faculty lead
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Appendix C
Gantt Chart
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Appendix D
Prisma Flow Diagram
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